Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1984 Apr;44(1):28–32. doi: 10.1128/iai.44.1.28-32.1984

Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria.

I M Orme, F M Collins
PMCID: PMC263458  PMID: 6423543

Abstract

The efficacy of Mycobacterium bovis BCG immunization in mice with established pulmonary infections caused by atypical mycobacteria was studied. In all four strains of Mycobacterium tested (M. kansasii, M. simiae, M. avium, and M. scrofulaceum), intravenous inoculation with 10(6) BCG had no discernible effect upon the course of atypical mycobacterial infection within the lungs; despite this, however, all BCG-vaccinated groups of mice were fully resistant to a subsequent acute aerogenic challenge with M. tuberculosis H37Rv, regardless of the presence of the pulmonary atypical mycobacterial infections. Furthermore, animals infected with M. kansasii, M. simiae, or M. avium but not vaccinated with BCG expressed considerable antituberculous resistance within the lungs, resulting in significant prolonged survival of these animals. The relevance of these findings to the expression of antituberculous resistance in human populations in areas in which atypical mycobacteria are endemic and the failure of these findings to support the hypothesis that prior contact with atypical mycobacteria might in some way jeopardize or interfere with the efficacy of subsequent BCG vaccination are discussed.

Full text

PDF
31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collins F. M. Immunogenicity of various mycobacteria and the corresponding levels of cross-protection developed between species. Infect Immun. 1971 Dec;4(6):688–696. doi: 10.1128/iai.4.6.688-696.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Edwards M. L., Goodrich J. M., Muller D., Pollack A., Ziegler J. E., Smith D. W. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guérin. J Infect Dis. 1982 May;145(5):733–741. doi: 10.1093/infdis/145.2.733. [DOI] [PubMed] [Google Scholar]
  3. Hart P. D. Efficacy and applicability of mass B. C.G. vaccination in tuberculosis control. Br Med J. 1967 Mar 11;1(5540):587–592. doi: 10.1136/bmj.1.5540.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Orme I. M., Collins F. M. Resistance of various strains of mycobacteria to killing by activated macrophages in vivo. J Immunol. 1983 Sep;131(3):1452–1454. [PubMed] [Google Scholar]
  5. Palmer C. E., Long M. W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis. 1966 Oct;94(4):553–568. doi: 10.1164/arrd.1966.94.4.553. [DOI] [PubMed] [Google Scholar]
  6. Rook G. A., Bahr G. M., Stanford J. L. The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle. 1981 Mar;62(1):63–68. doi: 10.1016/0041-3879(81)90038-6. [DOI] [PubMed] [Google Scholar]
  7. Stanford J. L., Shield M. J., Rook G. A. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle. 1981 Mar;62(1):55–62. doi: 10.1016/0041-3879(81)90037-4. [DOI] [PubMed] [Google Scholar]
  8. Watson S. R., Collins F. M. The specificity of suppressor T cells induced by chronic Mycobacterium avium infection in mice. Clin Exp Immunol. 1981 Jan;43(1):10–19. [PMC free article] [PubMed] [Google Scholar]
  9. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Jan;119(1):107–159. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]
  10. YOUMANS G. P., PARLETT R. C., YOUMANS A. S. The significance of the response of mice to immunization with viable unclassified mycobacteria. Am Rev Respir Dis. 1961 Jun;83:903–905. doi: 10.1164/arrd.1961.83.6.903. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES